The other path for follow-ons |
| |
Abstract: | With follow-on biologics essentially dead in the water in the US, the decision of the world's largest generics manufacturer to invest in a platform for enhancing protein pharmacokinetics could pay dividends. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|